Ngā hua rapu - Geert D’Haens
- E whakaatu ana i te 1 - 20 hua o te 228
- Haere ki te Whārangi Whai Ake
-
1
Risks and benefits of biologic therapy for inflammatory bowel diseases mā Geert D’Haens
I whakaputaina 2007Revisão -
2
-
3
-
4
Anti-interleukin-23 agents for the treatment of ulcerative colitis mā Jurij Hanžel, Geert D’Haens
I whakaputaina 2019Revisão -
5
-
6
Emerging therapies for ulcerative colitis mā Jurij Hanžel, Melanie S. Hulshoff, Joep Grootjans, Geert D’Haens
I whakaputaina 2022Revisão -
7
Combination Immunosuppression in IBD mā Steven Bots, K Gecse, Murray L. Barclay, Geert D’Haens
I whakaputaina 2018Revisão -
8
-
9
Appendectomy protects against ulcerative colitis mā Paul Rutgeerts, Geert D’Haens, Martin Hiele, Karel Geboes, Gaston Vantrappen
I whakaputaina 1994Artigo -
10
-
11
Clinical guidelines for the management of pouchitis mā Darrell S. Pardi, Geert D’Haens, Bo Shen, Simon Campbell, Paolo Gionchetti
I whakaputaina 2009Artigo -
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Internal medicine
Disease
Gastroenterology
Crohn's disease
Ulcerative colitis
Inflammatory bowel disease
Surgery
Pathology
Randomized controlled trial
Infliximab
Alternative medicine
Clinical trial
Placebo
Immunology
Tumor necrosis factor alpha
Adverse effect
Physics
Adalimumab
Clinical endpoint
Intensive care medicine
Biology
Chemotherapy
Confidence interval
Cohort
Colitis
Cancer
Colorectal cancer
Maintenance therapy
Radiology